open access

Vol 45, No 2 (2013 Apr-Jun)
Original and clinical articles
Submitted: 2013-07-05
Accepted: 2013-07-05
Get Citation

Comparison of in vitro efficacy of ertapenem, imipenem and meropenem in the infections caused by the Enterobacteriaceae strains family

Aneta Guzek, Dariusz Tomaszewski, Zbigniew Rybicki, Andrzej Truszczyński, Mariusz Barański, Krzysztof Korzeniewski
DOI: 10.5603/AIT.2013.0015
·
Anaesthesiol Intensive Ther 2013;45(2):67-72.

open access

Vol 45, No 2 (2013 Apr-Jun)
Original and clinical articles
Submitted: 2013-07-05
Accepted: 2013-07-05

Abstract

BACKGROUND: The members of the bacterial Enterobacteriaceae family play an important role in the aetiology of many hospital infections. Some of them are able to produce β-lactamase, an enzyme which induces the resistance of those bacteria to penicillins, cephalosporins and, in severe infections, to penicillins with β-lactamase inhibitors. In this situation, the carbapenems become the drugs of choice. The objective of this study was to analyse the in vitro efficacy of three carbapenems: ertapenem, imipenem and meropenem against bacterial species of the Enterobacteriaceae family.

METHODS: A total of 99 bacterial species (including ten bacterial species producing the ESBL mechanism), isolated between September 2011 and March 2012 from diagnostic material collected from patients of surgical clinics in the department of motoskeletal system infections and the critical care unit, hospitalised in the Military Institute of Medicine in Warsaw, were analysed. The values of MIC 50 and MIC 90 were recorded.

RESULTS: All isolated bacterial species were susceptible to meropenem. One strain of Morganella morganii was resistant to imipenem, while one strain of Enterobacter cloaceae and one strain of Klebsiella pneumoniae were resistant to ertapenem. In the Enterobacteriaceae ESBL(-) group, the values of MIC 50 were 0.006 μg mL-1 for ertapenem, 0.19 μg mL-1 for imipenem, and 0.032 μg mL-1 for meropenem, and the MIC 90 values were: 0.25 μg mL-1, 0.5 μg mL-1 and 0.125 μg mL-1, respectively. In the Enterobacteriaceae ESBL(+) group, the values of MIC 50 were 0.38 μg mL-1, 0.25 μg mL-1, 0.064 μg mL-1, and the values of MIC 90 were 0.5 μg mL-1, 0.25 μg mL-1 and 0.125 μg mL-1, respectively.

CONCLUSIONS: All analysed carbapenems had high in vitro efficacy against both Enterobacteriaceae ESBL(-) and Enterobacteriaceae ESBL(+) bacterial species.

Abstract

BACKGROUND: The members of the bacterial Enterobacteriaceae family play an important role in the aetiology of many hospital infections. Some of them are able to produce β-lactamase, an enzyme which induces the resistance of those bacteria to penicillins, cephalosporins and, in severe infections, to penicillins with β-lactamase inhibitors. In this situation, the carbapenems become the drugs of choice. The objective of this study was to analyse the in vitro efficacy of three carbapenems: ertapenem, imipenem and meropenem against bacterial species of the Enterobacteriaceae family.

METHODS: A total of 99 bacterial species (including ten bacterial species producing the ESBL mechanism), isolated between September 2011 and March 2012 from diagnostic material collected from patients of surgical clinics in the department of motoskeletal system infections and the critical care unit, hospitalised in the Military Institute of Medicine in Warsaw, were analysed. The values of MIC 50 and MIC 90 were recorded.

RESULTS: All isolated bacterial species were susceptible to meropenem. One strain of Morganella morganii was resistant to imipenem, while one strain of Enterobacter cloaceae and one strain of Klebsiella pneumoniae were resistant to ertapenem. In the Enterobacteriaceae ESBL(-) group, the values of MIC 50 were 0.006 μg mL-1 for ertapenem, 0.19 μg mL-1 for imipenem, and 0.032 μg mL-1 for meropenem, and the MIC 90 values were: 0.25 μg mL-1, 0.5 μg mL-1 and 0.125 μg mL-1, respectively. In the Enterobacteriaceae ESBL(+) group, the values of MIC 50 were 0.38 μg mL-1, 0.25 μg mL-1, 0.064 μg mL-1, and the values of MIC 90 were 0.5 μg mL-1, 0.25 μg mL-1 and 0.125 μg mL-1, respectively.

CONCLUSIONS: All analysed carbapenems had high in vitro efficacy against both Enterobacteriaceae ESBL(-) and Enterobacteriaceae ESBL(+) bacterial species.

Get Citation

Keywords

infections, bacteria, Enterobacteriaceae, antibiotics, ertapenem, imipenem, meropenem

About this article
Title

Comparison of in vitro efficacy of ertapenem, imipenem and meropenem in the infections caused by the Enterobacteriaceae strains family

Journal

Anaesthesiology Intensive Therapy

Issue

Vol 45, No 2 (2013 Apr-Jun)

Pages

67-72

DOI

10.5603/AIT.2013.0015

Bibliographic record

Anaesthesiol Intensive Ther 2013;45(2):67-72.

Keywords

infections
bacteria
Enterobacteriaceae
antibiotics
ertapenem
imipenem
meropenem

Authors

Aneta Guzek
Dariusz Tomaszewski
Zbigniew Rybicki
Andrzej Truszczyński
Mariusz Barański
Krzysztof Korzeniewski

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl